Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Upstream Bio (UPB) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Upstream Bio (UPB) over the last 2 years, with Sep 2025 value amounting to -5,539.39%.

  • Upstream Bio's EBITDA Margin fell 242686.00% to -5,539.39% in Q3 2025 from the same period last year, while for Sep 2025 it was -5,020.08%, marking a year-over-year decrease of 203974.00%. This contributed to the annual value of -3,281.18% for FY2024, which is 159572.00% down from last year.
  • As of Q3 2025, Upstream Bio's EBITDA Margin stood at -5,539.39%, which was down 17.04% from -4,732.87% recorded in Q2 2025.
  • Upstream Bio's 5-year EBITDA Margin high stood at -1,511.43% for Q3 2023, and its period low was -5,656.01% during Q1 2025.
  • For the 3-year period, Upstream Bio's EBITDA Margin averaged around -3,757.22%, with its median value being -3,439.22% (2024).
  • Data for Upstream Bio's EBITDA Margin shows a maximum YoY plummeted of 331,023bps (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Upstream Bio's EBITDA Margin stood at -3,184.44% in 2023, then crashed by 110,887bps to -4,293.31% in 2024, then crashed by 242,686bps to -5,539.39% in 2025.
  • Its last three reported values are -5,539.39% in Q3 2025, -4,732.87% for Q2 2025, and -5,656.01% during Q1 2025.